The ORMP chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ORMP chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ORMP stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ORMP Detailed Price Forecast - CNN Money||View ORMP Detailed Summary - Google Finance|
|View ORMP Detailed Summary - Yahoo! Finance||View ORMP Stock Research & Analysis - Zacks.com|
|View ORMP Trends & Analysis - Trade-Ideas||View ORMP Major Holders - Barrons|
|View ORMP Call Transcripts - NASDAQ||View ORMP Breaking News & Analysis - Seeking Alpha|
|View ORMP Annual Report - CompanySpotlight.com||View ORMP OTC Short Report - OTCShortReport.com|
|View ORMP Fundamentals - TradeKing||View ORMP SEC Filings - Bar Chart|
|View Historical Prices for ORMP - The WSJ||View Performance/Total Return for ORMP - Morningstar|
|View the Analyst Estimates for ORMP - MarketWatch||View the Earnings History for ORMP - CNBC|
|View the ORMP Earnings - StockMarketWatch||View ORMP Buy or Sell Recommendations - MacroAxis|
|View the ORMP Bullish Patterns - American Bulls||View ORMP Short Pain Metrics - ShortPainBot.com|
|View ORMP Stock Mentions - StockTwits||View ORMP Stock Mentions - PennyStockTweets|
|View ORMP Stock Mentions - Twitter||View ORMP Investment Forum News - Investor Hub|
|View ORMP Stock Mentions - Yahoo! Message Board||View ORMP Stock Mentions - Seeking Alpha|
|View Insider Transactions for ORMP - SECform4.com||View Insider Transactions for ORMP - Insider Cow|
|View ORMP Major Holdings Summary - CNBC||View Insider Disclosure for ORMP - OTC Markets|
|View Insider Transactions for ORMP - Yahoo! Finance||View Institutional Holdings for ORMP - NASDAQ|
|View ORMP Stock Insight & Charts - FinViz.com||View ORMP Investment Charts - StockCharts.com|
|View ORMP Stock Overview & Charts - BarChart||View ORMP User Generated Charts - Trading View|
Oramed to Present at Cardiometabolic Health Congress
Posted on Tuesday October 23, 2018
Now in its 13th year, the Cardiometabolic Health Congress is the largest, US-based, multidisciplinary conference focused solely on the management of cardiometabolic risk and the prevention of cardiovascular and metabolic disease. Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by scientists at Jerusalem's Hadassah Medical Center.
Oramed Enrolls First Patient in Its Clinical Study for Oral Insulin in the Treatment of NASH
Posted on Thursday October 04, 2018
NEW YORK, Oct. 4, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has enrolled the first patient in an exploratory clinical study of its oral insulin capsule, ORMD-0801, in the treatment of nonalcoholic steatohepatitis (NASH). The three-month treatment study, recently approved by Israel's Ministry of Health, will assess the effectiveness of ORMD-0801 in reducing liver fat content, inflammation and fibrosis in patients with NASH. Data from preclinical studies and clinical studies of ORMD-0801 demonstrate Oramed's oral insulin capsule has the potential to reduce inflammation of the liver.
Is Oramed Pharmaceuticals Inc’s (NASDAQ:ORMP) Balance Sheet Strong Enough To Weather A Storm?
Posted on Thursday September 20, 2018
The direct benefit for Oramed Pharmaceuticals Inc (NASDAQ:ORMP), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-offRead More...
Oramed Receives FDA Clearance for IND Application for Its Oral GLP-1 Analog Capsule
Posted on Monday September 17, 2018
NEW YORK, Sept. 17, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for human trials of its oral GLP-1 analog capsule ORMD-0901. In a prior Phase 1 study on type 2 diabetic patients, Oramed's ORMD-0901 capsule was well tolerated and showed encouraging efficacy, including reducing blood sugar levels following a standard meal as compared to a placebo. Oramed's planned Phase 1 pharmacokinetic (PK) study is a fully-randomized, single-blind, placebo-controlled 4-way crossover study which will evaluate safety in addition to the pharmacokinetics of ORMD-0901 compared to placebo and to open label Byetta®, a GLP-1 analog currently on the market, in up to 15 healthy subjects.